Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05423379 (SPIRIT XLV PAS) for Coronary Artery Disease is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
Abbott Medical DevicesXIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS)
XIENCE Skypoint Large Vessel Post Approval Study
- SPIRIT XLV PAS
- ABT -CIP 10445
Coronary artery disease
XIENCE
Large Vessel
Skypoint
| Participant Group/Arm | Intervention/Treatment |
|---|---|
XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System Subjects who were implanted with XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System will be included. | XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) XIENCE Skypoint Large Vessel EECSS is composed of a L-605 CoCr stent and coated with poly (n-butyl methacrylate) (PBMA) primer and a drug coating formulation of polymer of vinylidene fluoride and hexafluoropropylene (PVDF-HFP)/everolimus pre-mounted on a balloon catheter delivery system. |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Number of participants with Target Lesion Failure (TLF) at 1 year | TLF is defined as the composite of cardiac death, myocardial infarction related to the target vessel (TV-MI), or ischemic driven target lesion revascularization (ID-TLR). | At 1 Year |
General Inclusion Criteria
Subject must be at least 18 years of age.
Subject or a legally authorized representative must provide written informed consent per site requirements.
Subject must have evidence of myocardial ischemia (STEMI, NSTEMI, Unstable Angina or Stable Angina) or who have silent ischemia with evidence of ischemia, appropriate for PCI treatment with DES. Subject with stable angina or silent ischemia must have objective sign of ischemia as suggested by one of the following:
- Abnormal stress or imaging stress test
- Abnormal computed tomography-fractional flow reserve (CT-FFR)
- Stenosis by visual estimation ≥ 70%
- Abnormal pressure-derived indexes (FFR, instantaneous wave-free ratio [iFR], or relative flow reserve [RFR])
Subject must agree not to participate in any other clinical study for a period of one year following the index procedure.
Angiographic Inclusion Criteria
Patients who have lesion(s) in a vessel with reference vessel diameter > 4.25 mm and ≤ 5.25 mm as the target lesion
Patients who receive at least one Skypoint LV stent
- Lesions with RVD ≤ 4.25 mm should be treated as the non-target lesions during the index procedure with commercially available XIENCE family of stents
- Up to three lesions (target and non-target) in two coronary vessels can be treated at the index procedure.
General Exclusion Criteria
- Patients who have contraindications of the Skypoint LV per the IFU
- Subject has active symptoms and/or a positive test result of COVID-19 or other rapidly spreading novel infectious agent within the prior 2 months.
Angiographic Exclusion Criteria:
Patients who require three vessel treatment.
If left main coronary artery (LMCA) is the intended target vessel, patients who have unprotected left main disease with the SYNTAX Score ≥ 23
- Unprotected LM disease with a SYNTAX score ≤ 22 (site-assessment) can be treated as the target lesion but not to exceed 40% of the study population
- A heart team consensus approach per site's standard of care (SOC) to enhance patient protection and optimal clinical practice for the left main treatment is required.
Abbott Medical Devices185 active trials to exploreMidi-Pyrenees
Rhone
Arkansas
Florida
Kansas
Nebraska
New York
Pennsylvania
South Carolina
Texas